Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66945 | 0.94 | SCN5A (0.43) | SCN5ACYP19A1SLC6A3CACNA1BTBXA2R | |
| SCHEMBL67251 | 0.88 | CYP19A1 (0.41) | SCN5ACYP19A1CACNA1BMAPK1MITF | |
| SCHEMBL21855589 | 0.83 | CYP19A1 (0.45) | CYP19A1CACNA1BMAPK1TSHRHTR2A | |
| SCHEMBL7235720 | 0.82 | HRH1 (0.54) | CYP19A1HTR2AHRH1 | |
| SCHEMBL12860041 | 0.81 | HIF1A (0.31) | SCN5ASLC6A3TBXA2R | |
| SCHEMBL6179732 | 0.81 | SLC6A3 (0.33) | SCN5ACYP19A1SLC6A3TBXA2R | |
| SCHEMBL6963246 | 0.80 | SERPINH1 (0.39) | SCN5ACYP19A1CACNA1BMAPK1MITF | |
| SCHEMBL26109029 | 0.77 | IDO1 (0.32) | CYP19A1SLC6A3LMNAHTTMEN1 | |
| SCHEMBL6223969 | 0.77 | IDO1 (0.32) | CYP19A1SLC6A3LMNAHTTMEN1 | |
| SCHEMBL65457 | 0.75 | CACNA2D1 (0.37) | CYP19A1CACNA1BMAPK1CACNA1CMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0577171-B1 | Use of piperazine acetamide derivatives against reperfusion damage | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | claimed |
| EP-0577171-A2 | Use of piperazine acetamide derivatives against reperfusion damage | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-05 | — | — | EP | claimed |
| EP-0455789-A1 | METHOD OF PREVENTING OR LIMITING REPERFUSION DAMAGE. | JANSSEN PHARMACEUTICA NV (BE) | 1991-11-13 | — | — | EP | claimed |
| WO-1991007967-A2 | METHOD OF PREVENTING OR LIMITING REPERFUSION DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-13 | — | — | WO | claimed |
| WO-2020033909-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-02-13 | — | — | WO | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
| EP-0577171-B1 | Use of piperazine acetamide derivatives against reperfusion damage | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | disclosed |
| US-5840896-A | PREPARING 2-AMINOCARBONYL-N-(4-AMINO-2,6-DICHLOROPHENYL)-4-(5,5-BIS(4-FLUOROPHENYL) -PENTYL)-1-PIPERAZINEACETAMIDE; CYCLIZATION; HYDROGENATION CATALYSIS; REDUCTIVE N-ALKYLATION | JANSSEN PHARMACEUTICA, N.V. (BE) | 1998-11-24 | — | — | US | disclosed |
| US-5840896-A | PREPARING 2-AMINOCARBONYL-N-(4-AMINO-2,6-DICHLOROPHENYL)-4-(5,5-BIS(4-FLUOROPHENYL) -PENTYL)-1-PIPERAZINEACETAMIDE; CYCLIZATION; HYDROGENATION CATALYSIS; REDUCTIVE N-ALKYLATION | JANSSEN PHARMACEUTICA, N.V. (BE) | 1998-11-24 | — | — | US | disclosed |
| EP-0455789-B1 | METHOD OF PREVENTING OR LIMITING REPERFUSION DAMAGE | JANSSEN PHARMACEUTICA NV (BE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0577171-A2 | Use of piperazine acetamide derivatives against reperfusion damage | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | SCN5A 179/4885CYP19A1 1083/4885SLC6A3 520/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | SCN5A 179/4885CYP19A1 1083/4885SLC6A3 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.